Nkarta, Inc.
General ticker "NKTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $153.0M (TTM average)
Nkarta, Inc. follows the US Stock Market performance with the rate: 28.2%.
Estimated limits based on current volatility of 2.4%: low 1.76$, high 1.85$
Factors to consider:
- Total employees count: 150 (-8.0%) as of 2023
- Top business risk factors: Pandemic risks, Manufacturing risks, Supply chain disruptions, Cybersecurity threats, Limited operating history
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.08$, 3.79$]
- 2025-12-31 to 2026-12-31 estimated range: [0.79$, 2.69$]
Financial Metrics affecting the NKTX estimates:
- Positive: with PPE of -1.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -62.28 <= 0.33
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 81.40 > 63.39
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
Short-term NKTX quotes
Long-term NKTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $118.95MM | $131.65MM | $128.19MM |
| Operating Income | $-118.95MM | $-131.65MM | $-128.19MM |
| Non-Operating Income | $4.59MM | $14.84MM | $19.40MM |
| R&D Expense | $90.90MM | $96.77MM | $96.74MM |
| Income(Loss) | $-114.37MM | $-116.81MM | $-108.79MM |
| Profit(Loss)* | $-113.84MM | $-117.50MM | $-108.79MM |
| Stockholders Equity | $372.21MM | $273.29MM | $407.98MM |
| Assets | $472.94MM | $378.88MM | $501.20MM |
| Operating Cash Flow | $-57.00MM | $-86.16MM | $-99.70MM |
| Capital expenditure | $47.11MM | $28.15MM | $4.41MM |
| Investing Cash Flow | $-184.69MM | $79.02MM | $-129.56MM |
| Financing Cash Flow | $219.01MM | $0.69MM | $226.08MM |
| Earnings Per Share** | $-2.61 | $-2.40 | $-1.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.